Table 3. Associations between biomarker levels and the change from baseline to weeks 24 and 102 in bone mineral density for patients in the infliximab group.

Model	r2	b*	p Value
Spine BMD: % change from baseline to week 24
Baseline biomarker levels, n = 144	NS	NS	NS
% change from baseline to week 2 in biomarker levels, n = 135	NS	NS	NS
Spine BMD: % change from baseline to week 102
Baseline biomarker levels, n = 141	0.111
Osteocalcin		0.254	0.019
% change from baseline to week 2 in biomarker levels, n = 132	0.174
BAP		0.138	0.003
CTX		−0.035	0.024
VEGF		−0.081	0.046
Hip BMD: % change from baseline to week 24
Baseline biomarker levels, n = 143	0.153
Osteocalcin		0.084	0.002
% change from baseline to week 2 in biomarker levels, n = 135	0.121
BAP		0.027	0.019
CTX		−0.008	0.038
Hip BMD: % change from baseline to week 102
Baseline biomarker levels, n = 141	0.237
Osteocalcin		0.172	<0.0001
% change from baseline to week 2 in biomarker levels, n = 133	0.111
BAP		0.038	0.039

BAP, bone alkaline phosphatase; BMD, bone mineral density; CTX, C-terminal cross-linking telopeptide of type I collagen; NS, not significant; VEGF, vascular endothelial growth factor.

*Represents the intercept value in the linear regression equation (y = mx+b).